DreamCIS

드림씨아이에스 · 223250

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$80.3M (₩110.8B)

Overview

DreamCIS is a contract research organization (CRO), a company that handles clinical trials on behalf of pharmaceutical firms that want to reduce the cost and complexity of developing new drugs.

It provides services such as trial design, consulting, monitoring, data management, and regulatory filing support to drug developers. Listed on KOSDAQ, South Korea's tech and small-cap stock exchange, it manages the full outsourced research process from early trial planning through to post-market surveillance studies.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$48.3M
▲ +13.6% YoY
Operating profit · FY2025
US$3.8M
▲ +3.6% YoY
Net income · FY2025
US$5.4M
▲ +38.7% YoY

Revenue

  • FY2023US$34.7M
  • FY2024US$42.5M
  • FY2025US$48.3M

Operating profit

  • FY2023US$1.2M
  • FY2024US$3.7M
  • FY2025US$3.8M

Net income

  • FY2023US$2.8M
  • FY2024US$3.9M
  • FY2025US$5.4M

Key ratios (FY2025)

ROE
8.8%
Debt/Eq
88.6%
Op. margin
7.9%
Net margin
11.3%
Rev. YoY
▲ +13.6%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.